📰 Franco Conte News
Franco Conte News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Franco Conte. Real-time updates on events, politics, business and more.
June 28, 2023
Studies presented at ASCO 2023 answered questions about de-escalating treatment and how age impacts outcomes in HER2+ breast cancer.
June 15, 2023
Ten-year data from the Short-HER trial suggest that 1 year of adjuvant trastuzumab should remain standard care for HER2+ early breast cancer.
June 13, 2023
Ten-year data from the Short-HER trial suggest that 1 year of adjuvant trastuzumab should remain standard care for HER2+ early breast cancer.
June 4, 2023
CHICAGO — One-year of adjuvant trastuzumab remains the standard-of-care treatment duration for most patients with HER2-positive early breast cancer, according to study results presented at ASCO Annual Meeting.However, certain patients with low/intermediate HER2-positive early breast cancer may benefit from a shorter, 9-week course of trastuzumab (Herceptin, Genentech), researchers noted.